Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial - Poll - MDSpire

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS

  • February 17, 2026

  • 3 min

Share

Original Source(s)

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

  • February 17, 2026

Related Content

CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis

Large-cohort CSF proteomics from the Mann Lab identifies a 22-protein panel distinguishing MS from related diseases

  • March 11, 2026

  • 3 min
The quality of life in Ecuadorian patients with multiple sclerosis and neuromyelitis optica spectrum disorder and their association with anxiety, depression, fatigue, and disability

Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights